menu
    • menu

    Company profile for ABLi Therapeutics

    NEW Drugs in Dev: 4
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ABLi Therapeutics is pioneering innovative treatments for neurodegenerative diseases by targeting dysfunctional Abelson Tyrosine Kinases (Abl/c-Abl) with small-molecule inhibitors. Using our proprietary RAMP™ (Re-engineering Approach with Metabolism Preserved) platform, we optimize clinically validated kinase inhibitors to enhance brain penetration, potency, and safety. Our approach aims to intervene at the root of disease p...
    ABLi Therapeutics is pioneering innovative treatments for neurodegenerative diseases by targeting dysfunctional Abelson Tyrosine Kinases (Abl/c-Abl) with small-molecule inhibitors. Using our proprietary RAMP™ (Re-engineering Approach with Metabolism Preserved) platform, we optimize clinically validated kinase inhibitors to enhance brain penetration, potency, and safety. Our approach aims to intervene at the root of disease progression, offering promising therapies for conditions driven by kinase dysregulation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ABLi TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    ATLANTA, GA 30327-3812 USA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ablitherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Cosmoprof

    Cosmoprof

    Not Confirmed

    envelop Contact Supplier

    Cosmoprof

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CND Life Sciences Uses Syn-One In Ph2 Trial Parkinson’s Endpoint
    CND Life Sciences Uses Syn-One In Ph2 Trial Parkinson’s Endpoint

    11 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cnd-life-sciences-syn-one-biomarker-services-used-for-novel-parkinsons-disease-endpoint-in-phase-2-drug-trial-302610938.html

    PR NEWSWIRE
    11 Nov 2025
    Share Share
    Ablin Therapeutics Releases Phase 2 Trial Results
    Ablin Therapeutics Releases Phase 2 Trial Results

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164057/0/en/ABLi-Therapeutics-Reports-Final-Results-from-the-Phase-2-201-Trial-Evaluating-Risvodetinib-for-the-Treatment-of-Parkinson-s-Disease.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    ABLi Therapeutics to Speak at 2025 Parkinson’s Disease Congress
    ABLi Therapeutics to Speak at 2025 Parkinson’s Disease Congress

    15 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/15/3149944/0/en/ABLi-Therapeutics-to-Present-Clinical-Breakthrough-Lecture-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html

    GLOBENEWSWIRE
    15 Sep 2025
    Share Share
    ABLi Therapeutics Boosts Leadership Team and Board
    ABLi Therapeutics Boosts Leadership Team and Board

    28 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/28/3089398/0/en/ABLi-Therapeutics-Strengthens-Leadership-Team-and-Board-of-Directors.html

    GLOBENEWSWIRE
    28 May 2025
    Share Share
    ABLi Details FDA EOP2 Meeting On Risvodetinib For Parkinson's
    ABLi Details FDA EOP2 Meeting On Risvodetinib For Parkinson's

    21 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/21/3085719/0/en/ABLi-Therapeutics-Announces-Details-of-the-End-of-Phase-2-Meeting-with-FDA-for-Evaluation-of-Risvodetinib-as-a-Treatment-for-Parkinson-s-Disease.html

    GLOBENEWSWIRE
    21 May 2025
    Share Share
    ABLi Launches Focus on Developing to Tackle c-Abl Neuro Diseases
    ABLi Launches Focus on Developing to Tackle c-Abl Neuro Diseases

    12 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/12/3079103/0/en/ABLi-Therapeutics-Launches-with-a-Focus-on-Developing-Treatments-for-Neurodegenerative-Diseases-that-Arise-from-Activation-of-c-Abl-Kinases.html

    GLOBENEWSWIRE
    12 May 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search